Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 2/20 | 0.30 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207986 | 0.83 | CRHR1 (0.44) | OPRK1KMT2ASLC6A2HTTKDM4E | |
| SCHEMBL5210888 | 0.78 | CRHR1 (0.48) | KMT2AMAPT | |
| SCHEMBL5208719 | 0.77 | CRHR1 (0.35) | OPRK1KMT2ASLC6A2HTTKDM4E | |
| SCHEMBL11941841 | 0.75 | OPRK1 (0.52) | OPRK1KMT2AHTTKDM4EMAPT | |
| SCHEMBL3799140 | 0.69 | OPRK1 (0.50) | OPRK1KMT2AHTTKDM4EMAPT | |
| SCHEMBL14483945 | 0.68 | CYP2A6 (0.40) | KMT2AKDM4EMAPTMAPK1LMNA | |
| SCHEMBL17361074 | 0.68 | OPRK1 (0.48) | OPRK1KMT2AHTTKDM4EMAPT | |
| SCHEMBL11976473 | 0.67 | CYP2A6 (0.50) | KMT2AKDM4EMAPTMAPK1 | |
| SCHEMBL10330908 | 0.66 | KMT2A (0.49) | OPRK1KMT2AHTTKDM4EMAPT | |
| SCHEMBL2808229 | 0.66 | CCR1 (0.54) | KMT2ASLC6A2HTTKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341793-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20040266799-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6747034-B2 | CORTICOTROPIN-RELEASING FACTOR (CRF); SUCH AS 4-CHLORO-2-METHYL-5-NITRO-8-(2,4-DICHLORO)PHENYL-1,7-NAPHTHYRIDINE FOR TREATING STROKE, ANXIETY, DEPRESSION, AND/OR IRRITABLE BOWEL SYNDROME | NEUROCRINE BIOSCIENCES, INC. | 2004-06-08 | — | — | US | disclosed |
| EP-1341793-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020151557-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC | 2002-10-17 | — | — | US | disclosed |
| WO-2002040480-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266799-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | OPRK1 96/4885KMT2A 4376/4885SLC6A2 64/4885 |
| US-20020151557-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | OPRK1 96/4885KMT2A 4376/4885SLC6A2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.